RecruitingChronic Kidney Disease (CKD)
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Eligible age
18–70 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Sponsor: Regeneron Pharmaceuticals
You may qualify if…
- ✓ 1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
- ✓ 2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
- ✓ 3. Willing and able to comply with clinic visits and study-related procedures
- ✓ 4. Provide informed consent signed by study patient or legally acceptable representative
You may not qualify if…
- ✕ 1.There are no exclusion criteria for this study.
- ✕ Note: Other protocol defined Inclusion/Exclusion criteria may apply
Where it's recruiting
California
Los Angeles · Orange · San Francisco
Connecticut
New Haven
Illinois
Chicago
Maryland
Baltimore
Minnesota
Minneapolis
New York
New York
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT05106387 · last updated 2026-07-20